Replies to post #202458 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Edit: from the biotech showcase:

"Among patients with the severest form of psoriasis in study, those having a baseline IGA score of 3 (moderate), the primary endpoint was met in 46% of patients who received 200mg per day. These data were derived from analyses of all patients"


Again that is very promising. To go from 3 to 1 or even 0 is like PASI 90. I think Otezla was like 8% PASI 90

Have a great weekend all!!!

[BonelessCat]

Also, one shouldn’t hold a single metric in isolation. For example, response showed a clear dose dependence from lowest to highest where the lowest was in line with placebo, middle dose showed response signals, and the highest administered dose was clearly superior to the placebo. Yes, the trial wasn’t powered as a pivotal study (sarcastic “no shit” here), but three points on a graph are sufficient to see a very promising dose dependent efficacy curve.

One can’t and shouldnt ignore all other data and only focus on the low subject numbers.

[To infinity and beyond!]

maybe you are onto something here with respect to scales and using only the worst patients in the study as a subgroup. I need some time to think about it, since the subgroup stuff was not something I have paid any attention to. The problem would be that there are so few patients - i would think, without looking this morning- that meet those criteria- moderate to worse disease at the 200 mg dose.

But I will be only too happy to tip my cap to you if I have it wrong. There must be a slide somewhere that makes your point in the IP slide deck

[DesireToLearn]

Fully agree